Cartesian Therapeutics, Inc. (RNAC) Tuesday announced positive updated data from the Phase 2b trial of Descartes-08 in people with myasthenia gravis (MG), an autoimmune disease that causes weakness in the voluntary muscles. The company's shares were up more than 5 percent in pre-market.
As previously announced, the trial had met its primary goal.
New data from the Phase 2b study showed that Descartes-08 provided deep and durable improvements over time for MG patients, with 5.5 reduction in MG Activities of Daily Living (MG-ADL) at Month 4. Durable responses were observed through Month 12, with 80 percent of participants showed a reduction in MG-ADL score of at least 2 points.
A Phase 3 study of Descartes-08, dubbed AURORA, is planned to begin in the first half of 2025.
Cartesian Therapeutics stock had closed at $19.57, up 3.93 percent on Monday. It has traded in the range of $11.66 - $41.87 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.